FoundationOne Liquid CDx
Blood-based 324-gene comprehensive genomic profiling and companion-diagnostic test for advanced solid tumors. Regulatory claims are PMA-, supplement-, biomarker-, therapy- and indication-scoped.
- Developer
- Foundation Medicine
- Intended use
- Other
- Cancer scope
- Metastatic castration-resistant prostate cancer
- Specimen
- Peripheral whole blood, Plasma
- Molecular modality
- Copy number, DNA mutation
- Current version
- Current FoundationOne Liquid CDx 324-gene commercial lineage
- Evidence context
- 1 structured studies · 0 indexed performance results · 6 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.